You can buy or sell RETA and other stocks, options, ETFs, and crypto commission-free!
Reata Pharmaceuticals, Inc. Class A Common Stock, also called Reata Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Read More Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
52 Week High
52 Week Low
Seeking AlphaMay 24
Reata Bardoxolone Trial Success Likely, But Still Just A Hold
Reata Pharmaceuticals (RETA) is a late clinical stage biotechnology company with a chronic kidney disease therapy due to release results later this year.
Seeking AlphaMay 9
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2019 Results - Earnings Call Transcript
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q1 2019 Results Earnings Conference Call May 9, 2019 8:00 AM ET Company Participants Vinny Jindal - VP, Strategy Warren Huff - CEO Colin Meyer - CMO Jason Wilson - CFO Conference Call Participants Yigal Nochomovitz - Citigroup Adam Walsh - Stifel Joseph Swartz - SVP Leerink Maury Raycroft - Jefferies Brian Skorney - Baird Operator Good day, ladies and gentlemen, and welcome to the Reata Pharmaceuticals First Quarter Financial Results and Update on Devel...
Yahoo FinanceMay 9
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.03% and -1.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Reata Pharmaceuticals, Inc. (RETA) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise ...
Expected Aug 8, Pre-Market